drugset

drugset / Trial / NCT01559961

Safety Study of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome

NCT01559961 ↗

Phase 1 Completed 28 enrolled Trillium Therapeutics Inc.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and pharmacokinetics of TTI-1612 in women with interstitial cystitis/bladder pain syndrome.

Timeline

Start: 2012-03
Primary completion: 2013-02
Completion: 2013-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TTI-1612	Unknown	—	Other

Indications